Pneumonia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Infection Type (Hospital-acquired Pneumonia [HAP], Community-acquired Pneumonia [CAP], Ventilator-associated Pneumonia [VAP]), By Type (Drugs, Preventive Vaccines, Oxygen Therapy), By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Others), By Region and Competition, 2019-2029F

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2025-2029

Market Size (2023)

USD 2.21 Billion

CAGR (2024-2029)

7.16%

Fastest Growing Segment

Community-acquired Pneumonia [CAP]

Largest Market

North America

Market Size (2029)

USD 3.35 Billion

 

Market Overview

Global Pneumonia Therapeutics Market was valued at USD 2.21 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 7.16% through 2029. The global pneumonia therapeutics market is a dynamic and crucial segment of the pharmaceutical and healthcare industry, focused on combating a prevalent and life-threatening respiratory infection known as pneumonia. Pneumonia, characterized by inflammation in the air sacs of the lungs, can be caused by various pathogens, including bacteria, viruses, and fungi. It poses a significant public health challenge worldwide, affecting individuals of all age groups but particularly impacting the elderly, children, and those with weakened immune systems. As a result, the market for pneumonia therapeutics has witnessed substantial growth and innovation in recent years.

The market is primarily driven by the rising incidence of pneumonia, attributed to factors such as aging populations, increased antibiotic resistance, and the spread of infectious diseases. This has led to a growing demand for effective treatment options. Pneumonia therapeutics include a wide range of pharmaceuticals, such as antibiotics, antivirals, and supportive care medications. The development of novel antimicrobial agents and advancements in diagnostic techniques have expanded treatment options, resulting in a surge in research and development activities. The COVID-19 pandemic has accelerated market growth, as severe COVID-19 cases often present with pneumonia-like symptoms, increasing the demand for pneumonia therapeutics and related healthcare services. Additionally, vaccination efforts and public health campaigns play a crucial role in preventing pneumonia, indirectly influencing the market.

Key Market Drivers

Rising Pneumonia Incidence

The escalating incidence of pneumonia is a key driver behind the growth of the global pneumonia therapeutics market. Pneumonia, a common respiratory infection, affects individuals of all ages and continues to be a significant public health concern. Several factors contribute to the rising incidence of pneumonia, making effective therapeutics a necessity. First, the aging population, especially in developed countries, is at an increased risk of pneumonia due to weakened immune systems and age-related health conditions. This demographic shift has led to a surge in pneumonia cases among the elderly, resulting in a higher demand for treatment options. The emergence of antibiotic-resistant bacteria poses a significant challenge in treating pneumonia. Antibiotic resistance has made it more difficult to combat bacterial pneumonia effectively, necessitating the development of novel antimicrobial agents. Pharmaceutical companies are investing in research and development to create more potent antibiotics, addressing the increasing prevalence of drug-resistant strains and further propelling the pneumonia therapeutics market.

The persistence of infectious diseases and the global spread of various pathogens contribute to the higher incidence of pneumonia. These infectious agents, including bacteria and viruses, can cause both community-acquired and hospital-acquired pneumonia. The ongoing threat of outbreaks and pandemics, such as the COVID-19 pandemic, underscores the importance of effective pneumonia treatment and prevention, thus driving market growth. The rising incidence of pneumonia is a critical factor boosting the global pneumonia therapeutics market. The aging population, antibiotic resistance, and the continued prevalence of infectious diseases are major contributors to this trend. These factors highlight the need for ongoing research, innovation, and development in the field of pneumonia therapeutics to meet the growing demand and provide effective treatment options for individuals suffering from this potentially life-threatening respiratory infection.

Advances in Antimicrobial Agents

Advances in antimicrobial agents are playing a pivotal role in boosting the global pneumonia therapeutics market. Pneumonia, a respiratory infection caused by various pathogens, including bacteria and viruses, has been a persistent healthcare concern. However, the development of innovative antimicrobial agents has significantly improved the effectiveness of pneumonia treatment, thereby propelling market growth. The most critical drivers is the continuous evolution of antibiotic therapy. Over time, bacteria have developed resistance to many commonly used antibiotics, creating a challenge in treating bacterial pneumonia effectively. To address this issue, researchers have been actively engaged in the discovery and development of new antibiotics that are more potent against drug-resistant strains. These new antimicrobial agents are not only enhancing patient outcomes but also providing pharmaceutical companies with opportunities to introduce novel, effective products to the market.

The emergence of antiviral medications has significantly expanded the therapeutic options for viral pneumonia. Advancements in antiviral drugs have allowed for more targeted and efficacious treatment of viral pneumonia, including influenza and COVID-19, which are major contributors to pneumonia cases. The availability of antiviral agents with enhanced effectiveness has not only improved patient recovery but also broadened the scope of the pneumonia therapeutics market, addressing a wider spectrum of pathogens. The development of combination therapies, involving both antibiotics and antiviral agents, is another noteworthy advancement. These combination treatments offer a multifaceted approach to tackling pneumonia, especially in cases where the causative agents may be mixed or where bacterial and viral co-infections occur. Such therapies have become a game-changer in pneumonia management, allowing for more precise and comprehensive patient care.

Diagnostic Advancements

Diagnostic advancements have become a significant driving force behind the growth of the global pneumonia therapeutics market. Accurate and timely diagnosis is pivotal in ensuring the appropriate and effective treatment of pneumonia, and recent progress in diagnostic techniques is revolutionizing the way healthcare providers approach this respiratory infection. The diagnostic advancements is the utilization of molecular diagnostic methods, such as polymerase chain reaction (PCR) and nucleic acid tests. These techniques have greatly improved the precision and speed with which pneumonia can be diagnosed. Molecular diagnostics enable healthcare professionals to identify the specific causative agents of pneumonia, whether they are bacteria, viruses, or fungi, allowing for more targeted and tailored treatment regimens. This not only enhances patient outcomes but also helps in reducing the misuse of antibiotics, thus contributing to the global efforts to combat antimicrobial resistance.

Advancements in radiological imaging techniques, such as computed tomography (CT) scans and high-resolution chest X-rays, have played a crucial role in the diagnosis and assessment of pneumonia. These technologies offer a detailed view of the lungs, helping clinicians identify the extent and severity of lung involvement. As a result, physicians can make more informed decisions about the appropriate course of treatment, including the need for hospitalization, oxygen therapy, or specific medications. Point-of-care testing (POCT) has also gained prominence in the diagnosis of pneumonia, especially in primary care settings and resource-limited environments. Rapid diagnostic tests can identify pneumonia pathogens within minutes, enabling quicker initiation of appropriate treatment and reducing the time to diagnosis. This is particularly important in cases of severe or atypical pneumonia, where early intervention is critical.




Download Free Sample Report

Key Market Challenges

Antibiotic Resistance

Antibiotic resistance stands as one of the foremost challenges in the global pneumonia therapeutics market, significantly impacting the efficacy of treatment options and posing a serious threat to public health. Pneumonia, a common and potentially life-threatening respiratory infection, is often caused by bacterial pathogens, and antibiotics have been a primary line of defense against these infections. However, the emergence and spread of antibiotic-resistant strains of bacteria are severely hindering the effectiveness of existing pneumonia treatments. Antibiotic resistance occurs when bacteria develop mechanisms to withstand the effects of antibiotics, rendering these drugs less or entirely ineffective in treating bacterial infections. In the context of pneumonia, this poses a major problem, as timely and appropriate antibiotic treatment is essential to mitigate the severity of the disease. Several factors contribute to antibiotic resistance in the context of pneumonia, and they have significant implications for the global pneumonia therapeutics market:

The widespread use and sometimes misuse of antibiotics have accelerated the development of resistance. In many cases, antibiotics are prescribed without proper diagnostic confirmation of bacterial pneumonia. This overuse contributes to the selective pressure on bacteria, favoring the growth of resistant strains. The development of new antibiotics has been slow in recent years, partly due to the high costs and challenges associated with researching and bringing new antibiotics to market. This limited pipeline of novel antibiotics further exacerbates the issue of antibiotic resistance in pneumonia treatment.

Delayed Diagnosis 

Pneumonia can present with a wide range of symptoms, some of which may overlap with other respiratory conditions. In some cases, patients may not display the classic signs of pneumonia, such as high fever, productive cough, and chest pain, leading to initial misdiagnosis or delayed recognition of the infection. The availability and accuracy of diagnostic tools can vary significantly across regions and healthcare settings. In resource-limited areas, access to advanced diagnostic tests, such as radiological imaging or molecular diagnostics, may be limited, leading to delays in diagnosis. The severity of pneumonia can be underestimated, especially in cases where the patient's clinical condition does not immediately appear critical. This can lead to a delay in initiating appropriate treatment, which can be crucial in preventing the progression of the disease to a more severe stage.

Pneumonia can be complicated by other respiratory conditions or co-infections, making diagnosis more challenging. In such cases, it may take longer to identify the underlying cause of the patient's respiratory distress. Delayed diagnosis can result in delayed treatment initiation, leading to worsened patient outcomes. Pneumonia can progress rapidly, and every hour of delay in treatment can increase the risk of complications and mortality. Prolonged hospital stays, more aggressive treatment regimens, and the need for intensive care due to delayed diagnosis can result in higher healthcare costs. Patients with severe pneumonia may require more extensive and expensive interventions. The delayed diagnosis and treatment of pneumonia can strain healthcare resources, particularly in high-incidence areas or during outbreaks. Overburdened healthcare systems can impact the quality of care provided to pneumonia patients.

Key Market Trends

Advancements in Antibiotics and Antiviral Therapies

Advancements in antibiotics and antiviral therapies are playing a pivotal role in boosting the global pneumonia therapeutics market. Pneumonia, a respiratory infection often caused by bacteria and viruses, has witnessed significant progress in the development of more effective treatment options, thanks to ongoing innovations in antimicrobial agents. The trends in pneumonia therapeutics is the continuous development of novel antibiotics that are potent against drug-resistant bacterial strains. This breakthrough is particularly crucial as antibiotic resistance has become a formidable challenge in treating pneumonia. The emergence of these new antibiotics has enhanced the precision of treatment for pneumonia, ensuring that patients receive effective care, even when confronted with resistant pathogens.

The evolution of antiviral medications has expanded the treatment options for viral pneumonia. Antiviral advancements have not only improved patient outcomes but also broadened the scope of the pneumonia therapeutics market, allowing healthcare providers to address a wider spectrum of pathogens causing respiratory infections. The trend of combination therapies, involving both antibiotics and antiviral agents, has gained prominence. This approach provides a multifaceted strategy to pneumonia management, enabling comprehensive treatment plans, especially in cases of bacterial and viral co-infections or mixed causative agents. The synergistic effects of combination therapies often result in better patient outcomes, emphasizing the evolving landscape of pneumonia treatment.

Combination Therapies

Combination therapies are emerging as a significant driving force behind the growth of the global pneumonia therapeutics market. Pneumonia, a respiratory infection caused by various pathogens, often presents complex challenges in treatment, with mixed causative agents or bacterial and viral co-infections. In response to these challenges, combination therapies have gained prominence, providing a multifaceted approach to pneumonia management.  Pneumonia cases with mixed or resistant pathogens may not respond optimally to a single treatment approach. Combination therapies combine the strengths of different medications, providing a more comprehensive and effective treatment, particularly in severe or complicated cases.

Pneumonia can be caused by a variety of pathogens, and accurately identifying the causative agent can be challenging. Combination therapies do not rely on pinpointing the exact pathogen but rather offer a broad-spectrum approach, ensuring that patients receive effective treatment even when the specific agent is unknown. The use of multiple agents with different mechanisms of action can help mitigate the development of antibiotic or antiviral resistance. By targeting pathogens through various pathways, combination therapies make it more challenging for them to adapt and become resistant. Combination therapies can be tailored to individual patient needs, taking into account their clinical presentation, coexisting conditions, and the severity of pneumonia. This personalized approach optimizes patient care. Clinical studies have shown that combination therapies often lead to better patient outcomes, including faster recovery, reduced complications, and shorter hospital stays.

Segmental Insights

Infection Type Insights

Based on Infection Type, Community-acquired pneumonia (CAP) have emerged as the fastest growing segment in the Global Pneumonia Therapeutics Market in 2023. CAP is more prevalent than HAP or VAP. It affects a larger population, including individuals of all ages, from children to the elderly. The greater incidence of CAP results in a higher demand for pneumonia treatment options in both developed and developing regions. Many CAP cases can be managed on an outpatient or ambulatory care basis, which means that patients are often treated in non-hospital settings. This results in a substantial market demand for therapeutics that can be used outside of the hospital environment. CAP can be caused by various pathogens, including bacteria, viruses, and fungi. This diversity necessitates a range of pneumonia therapeutics to address the different etiologies, further fueling demand in the market.

Type Insights

Based on Type, Preventive Vaccines have emerged as the dominant segment in the Global Pneumonia Therapeutics Market in 2023. Vaccines are highly effective in preventing pneumonia, reducing both its incidence and severity. This preventive strategy is more efficient and cost-effective than treating pneumonia after onset. Governments and health organizations worldwide prioritize vaccination programs to manage and prevent pneumonia. Extensive immunization campaigns have significantly increased vaccine coverage, bolstering the dominance of preventive vaccines in the market. Preventive vaccines lower overall healthcare costs by reducing the need for hospitalizations, medical treatments, and long-term care, making them economically advantageous compared to therapeutic interventions. Continuous R&D efforts have resulted in more effective and safer vaccines. Technological innovations, such as the development of conjugate and pneumococcal vaccines, have improved their efficacy and acceptance, further cementing their market leadership. 


           


Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominant region in the Global Pneumonia Therapeutics Market in 2023, holding the largest market share. The region is a hub for pharmaceutical and biotechnology research and development. It is home to many leading pharmaceutical companies and research institutions that actively invest in the development of innovative pneumonia therapeutics, including antibiotics, antiviral drugs, and vaccines. North America has stringent regulatory bodies such as the U.S. Food and Drug Administration (FDA) and Health Canada that provide a rigorous but well-defined pathway for drug approval. This regulatory environment promotes the development and commercialization of new pneumonia treatments, ensuring their safety and efficacy. Pneumonia remains a significant healthcare concern in North America, especially among vulnerable populations such as the elderly, young children, and individuals with underlying health conditions. The region's aging population and the prevalence of comorbidities contribute to a continued high demand for pneumonia therapeutics. 

Recent Development 

  • In May 2023, the U.S. Food and Drug Administration approved Xacduro (sulbactam for injection; durlobactam for injection), a new treatment for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex, for patients aged 18 and older. The World Health Organization identifies Acinetobacter species as top critical bacterial pathogens posing significant threats to human health, underscoring the urgent need for new treatment options in the face of rising global antimicrobial resistance.

Key Market Players

  • Pfizer Inc.
  • AstraZeneca Plc.
  • Eli Lilly & company
  • F. Hoffmann-La Roche Ltd.
  • Viatris Inc. 
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Limited

 By Infection Type

By Type

By Drug Class

By End User

By Region
  • Hospital-acquired Pneumonia [HAP]
  • Community-acquired Pneumonia [CAP]
  • Ventilator-associated Pneumonia [VAP]
  • Drugs
  • Preventive Vaccines
  • Oxygen Therapy
  • Antibacterial Drugs
  • Antiviral Drugs
  • Antifungal Drugs
  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Others
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global Pneumonia Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Pneumonia Therapeutics Market, By Infection Type:

o Hospital-acquired Pneumonia [HAP]

o Community-acquired Pneumonia [CAP]

o Ventilator-associated Pneumonia [VAP])

  • Pneumonia Therapeutics Market, By Type:

o Drugs

o Preventive Vaccines

o Oxygen Therapy

  • Pneumonia Therapeutics Market, By Drug Class:

o Antibacterial Drugs

o Antiviral Drugs

o Antifungal Drugs

  • Pneumonia Therapeutics Market, By End User:

o Hospitals and Clinics

o Ambulatory Surgical Centers

o Others

  • Pneumonia Therapeutics Market, By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ United Kingdom

§ Italy

§ Germany

§ Spain

o Asia Pacific

§ China

§ India

§ Japan

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pneumonia Therapeutics Market.

Available Customizations:

Global Pneumonia Therapeutics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Pneumonia Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Global Pneumonia Therapeutics Market Outlook

4.1.  Market Size & Forecast

4.1.1.    By Value

4.2.  Market Share & Forecast

4.2.1.    By Infection Type (Hospital-acquired Pneumonia [HAP], Community-acquired Pneumonia [CAP], Ventilator-associated Pneumonia [VAP])

4.2.2.    By Type (Drugs, Preventive Vaccines, Oxygen Therapy)

4.2.3.    By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs)

4.2.4.    By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Others)

4.2.5.    By Region

4.2.6.    By Company (2023)

4.3.  Market Map

4.3.1.    By Infection Type 

4.3.2.    By Type

4.3.3.    By Drug Class

4.3.4.    By End User

4.3.5.    By Region

5.    Asia Pacific Pneumonia Therapeutics Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Infection Type 

5.2.2.    By Type

5.2.3.    By Drug Class

5.2.4.    By End User

5.2.5.    By Country

5.3.  Asia Pacific: Country Analysis

5.3.1.    China Pneumonia Therapeutics Market Outlook

5.3.1.1.        Market Size & Forecast

5.3.1.1.1.           By Value

5.3.1.2.        Market Share & Forecast

5.3.1.2.1.           By Infection Type 

5.3.1.2.2.           By Type

5.3.1.2.3.           By Drug Class

5.3.1.2.4.           By End User

5.3.2.    India Pneumonia Therapeutics Market Outlook

5.3.2.1.        Market Size & Forecast

5.3.2.1.1.           By Value

5.3.2.2.        Market Share & Forecast

5.3.2.2.1.           By Infection Type 

5.3.2.2.2.           By Type

5.3.2.2.3.           By Drug Class

5.3.2.2.4.           By End User

5.3.3.    Australia Pneumonia Therapeutics Market Outlook

5.3.3.1.        Market Size & Forecast

5.3.3.1.1.           By Value

5.3.3.2.        Market Share & Forecast

5.3.3.2.1.           By Infection Type 

5.3.3.2.2.           By Type

5.3.3.2.3.           By Drug Class

5.3.3.2.4.           By End User

5.3.4.    Japan Pneumonia Therapeutics Market Outlook

5.3.4.1.        Market Size & Forecast

5.3.4.1.1.           By Value

5.3.4.2.        Market Share & Forecast

5.3.4.2.1.           By Infection Type 

5.3.4.2.2.           By Type

5.3.4.2.3.           By Drug Class

5.3.4.2.4.           By End User

5.3.5.    South Korea Pneumonia Therapeutics Market Outlook

5.3.5.1.        Market Size & Forecast

5.3.5.1.1.           By Value

5.3.5.2.        Market Share & Forecast

5.3.5.2.1.           By Infection Type 

5.3.5.2.2.           By Type

5.3.5.2.3.           By Drug Class

5.3.5.2.4.           By End User

6.    Europe Pneumonia Therapeutics Market Outlook

6.1.  Market Size & Forecast

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Infection Type 

6.2.2.    By Type

6.2.3.    By Drug Class

6.2.4.    By End User

6.2.5.    By Country

6.3.  Europe: Country Analysis

6.3.1.    France Pneumonia Therapeutics Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Infection Type 

6.3.1.2.2.           By Type

6.3.1.2.3.           By Drug Class

6.3.1.2.4.           By End User

6.3.2.    Germany Pneumonia Therapeutics Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Infection Type 

6.3.2.2.2.           By Type

6.3.2.2.3.           By Drug Class

6.3.2.2.4.           By End User

6.3.3.    Spain Pneumonia Therapeutics Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Infection Type 

6.3.3.2.2.           By Type

6.3.3.2.3.           By Drug Class

6.3.3.2.4.           By End User

6.3.4.    Italy Pneumonia Therapeutics Market Outlook

6.3.4.1.        Market Size & Forecast

6.3.4.1.1.           By Value

6.3.4.2.        Market Share & Forecast

6.3.4.2.1.           By Infection Type 

6.3.4.2.2.           By Type

6.3.4.2.3.           By Drug Class

6.3.4.2.4.           By End User

6.3.5.    United Kingdom Pneumonia Therapeutics Market Outlook

6.3.5.1.        Market Size & Forecast

6.3.5.1.1.           By Value

6.3.5.2.        Market Share & Forecast

6.3.5.2.1.           By Infection Type 

6.3.5.2.2.           By Type

6.3.5.2.3.           By Drug Class

6.3.5.2.4.           By End User

7.    North America Pneumonia Therapeutics Market Outlook

7.1.  Market Size & Forecast

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Infection Type 

7.2.2.    By Type

7.2.3.    By Drug Class

7.2.4.    By End User

7.2.5.    By Country

7.3.  North America: Country Analysis

7.3.1.    United States Pneumonia Therapeutics Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Infection Type 

7.3.1.2.2.           By Type

7.3.1.2.3.           By Drug Class

7.3.1.2.4.           By End User

7.3.2.    Mexico Pneumonia Therapeutics Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Infection Type 

7.3.2.2.2.           By Type

7.3.2.2.3.           By Drug Class

7.3.2.2.4.           By End User

7.3.3.    Canada Pneumonia Therapeutics Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Infection Type 

7.3.3.2.2.           By Type

7.3.3.2.3.           By Drug Class

7.3.3.2.4.           By End User

8.    South America Pneumonia Therapeutics Market Outlook

8.1.  Market Size & Forecast

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Infection Type 

8.2.2.    By Type

8.2.3.    By Drug Class

8.2.4.    By End User

8.2.5.    By Country

8.3.  South America: Country Analysis

8.3.1.    Brazil Pneumonia Therapeutics Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Infection Type 

8.3.1.2.2.           By Type

8.3.1.2.3.           By Drug Class

8.3.1.2.4.           By End User

8.3.2.    Argentina Pneumonia Therapeutics Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Infection Type 

8.3.2.2.2.           By Type

8.3.2.2.3.           By Drug Class

8.3.2.2.4.           By End User

8.3.3.    Colombia Pneumonia Therapeutics Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Infection Type 

8.3.3.2.2.           By Type

8.3.3.2.3.           By Drug Class

8.3.3.2.4.           By End User

9.    Middle East and Africa Pneumonia Therapeutics Market Outlook

9.1.  Market Size & Forecast

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Infection Type 

9.2.2.    By Type

9.2.3.    By Drug Class

9.2.4.    By End User

9.2.5.    By Country

9.3.  MEA: Country Analysis

9.3.1.    South Africa Pneumonia Therapeutics Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Infection Type 

9.3.1.2.2.           By Type

9.3.1.2.3.           By Drug Class

9.3.1.2.4.           By End User

9.3.2.    Saudi Arabia Pneumonia Therapeutics Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Infection Type 

9.3.2.2.2.           By Type

9.3.2.2.3.           By Drug Class

9.3.2.2.4.           By End User

9.3.3.    UAE Pneumonia Therapeutics Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Infection Type 

9.3.3.2.2.           By Type

9.3.3.2.3.           By Drug Class

9.3.3.2.4.           By End User

10. Market Dynamics

10.1.             Drivers

10.2.             Challenges

11. Market Trends & Developments

11.1.             Recent Developments

11.2.             Product Launches

11.3.             Mergers & Acquisitions

12. Global Pneumonia Therapeutics Market: SWOT Analysis

13. Porter’s Five Forces Analysis

13.1.             Competition in the Industry

13.2.             Potential of New Entrants

13.3.             Power of Suppliers

13.4.             Power of Customers

13.5.             Threat of Substitute Product

14. Competitive Landscape

14.1.       Pfizer Inc.

14.1.1.         Business Overview

14.1.2.          Company Snapshot

14.1.3.          Products & Services

14.1.4.          Financials (In case of listed)

14.1.5.          Recent Developments

14.1.6.          SWOT Analysis

14.2. AstraZeneca Plc. 

14.3. Eli Lilly & company 

14.4. F. Hoffmann-La Roche Ltd. 

14.5. Viatris Inc.  

14.6. Teva Pharmaceutical Industries Ltd. 

14.7. Sanofi SA 

14.8. Novartis AG 

14.9. Sun Pharmaceutical Industries Ltd. 

14.10. Aurobindo Pharma Limited

15. Strategic Recommendations

16. About Us & Disclaimer 

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Pneumonia Therapeutics Market was estimated to be USD 2.21 Billion in 2023.

down-arrow

Pfizer Inc., AstraZeneca Plc., Eli Lilly & company were some of the key players operating in the Global Pneumonia Therapeutics Market.

down-arrow

Antibiotic Resistance and Delayed Diagnosis are the challenges faced by the Global Pneumonia Therapeutics Market in the upcoming years.

down-arrow

Rising Pneumonia Incidence and Advances in Antimicrobial Agents are the major drivers for the Global Pneumonia Therapeutics Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Pneumonia Therapeutics Market to Grow with a CAGR of 7.16% through 2029

May, 2024

Rising technological advancements are expected to drive the Global Pneumonia Therapeutics Market growth in the forecast period, 2025-2029.

Why Choose Us